Insight

Sonio: A four-year health tech success story for impact and financial investors

By Published On: October 8, 2024
Sonio: A four-year health tech success story for impact and financial investors

Annie Theriault is a managing partner at Cross-Border Impact Ventures (CBIV), an impact venture capital firm investing in women’s, children’s and adolescents’ health technology companies addressing large international markets. 

One in every 33 babies in Europe and the United States is born with a birth defect.

In 50 per cent of these cases, ultrasound did not detect these defects, making it impossible to provide timely treatment prenatally or at birth.

A late diagnosis could result in consequences including severe disability, or even death. 

Recognising how complex foetal medicine is, French company Sonio burst onto the healthtech scene in 2020.

Sonio offers AI-enhanced software that assists ultrasound practitioners and maternal and foetal specialists or healthcare professionals in detecting birth defects.

Sonio’s rapid growth during this time is a testament to its innovative spirit and commitment to transforming prenatal care through cutting-edge technology. 

Since its founding, Sonio has completed a series A funding round, raising $14 million.

The company also received FDA clearance and the CE mark for its Sonio Detect solution and secured a deal to have its technology deployed across the Pediatrix Medical Group in the U.S. Sonio’s contributions to the field of maternal and children’s health have earned the company global recognition and a presence at prestigious events such as the Society of Maternal-Fetal Medicine annual meeting and the HLTH Europe conference.

To cap its successes over the past four years, Sonio was acquired in August by Samsung Medison, a global medical equipment company and affiliate of Samsung Electronics.

The acquisition combines an established global ultrasound business with advanced AI to advance medical reporting technology and diagnostic software globally—including for underserved areas in healthcare—and will enable Sonio to pursue and accelerate its roadmap and mission.  

Streamlining Healthcare with One Comprehensive Solution

Sonio’s vision is ambitious yet crucial: to provide healthcare professionals with a single, integrated platform that supports the full continuum of prenatal care.

From the very first screening to the final exam, Sonio’s platform ensures that each stage of care is meticulously documented.

The goal is to eliminate missed malformations, improve diagnostic accuracy, and enhance both the efficacy and efficiency of healthcare providers. 

Building on this is Soniopedia, a game-changer in prenatal ultrasound training.

Soniopedia is an AI-enabled training solution designed to enhance the skills of ultrasound practitioners, enabling them to detect foetal malformations earlier and more accurately.

This training tool integrates seamlessly into Sonio’s existing platform, further extending its mission of improving maternal-foetal healthcare outcomes.

With the inclusion of Soniopedia, Sonio now offers a comprehensive solution that not only supports clinical diagnostics but also addresses the training needs of practitioners, further strengthening the continuum of care. 

Accessible Technology for a Global Impact

From the outset, Sonio has aimed to make its technology accessible worldwide, particularly in regions where quality healthcare is harder to reach.

By leveraging cloud-based technology, Sonio has made its software accessible remotely, empowering more healthcare professionals to provide timely consultations and second opinions.

This accessibility has been a cornerstone of Sonio’s mission to democratise prenatal care, ensuring that people in even the most underserved regions can benefit from advanced medical insights.

For investors like Cross-Border Impact Ventures, Sonio’s appeal was not only due to the commercial promise of the company, but also due to its positive impact in emerging markets.

As an impact-focused investment firm, Sonio’s expansion into countries like Brazil, Nigeria, and India made the investment especially exciting, showcasing the company’s ability to deliver cutting-edge healthcare solutions to areas where they are most needed. 

Unlike many companies that start their global expansion after stabilizing in one region, Sonio began scaling internationally at a remarkably early stage.

This early global footprint was particularly impressive for a France-based company and demonstrated the adaptability and broad applicability of their solution.

European companies, especially those in smaller markets, often find themselves expanding globally sooner than their U.S. counterparts, who can rely on the large domestic market.

Sonio exemplified this trend, showing that even with a smaller home market, they could scale effectively and serve a global need.

Clinical and Regulatory Rigor Led to Impact and Financial Success 

The Sonio software was conceived with the input of clinicians — including maternal foetal medicine doctors, nurses, and sonographers — alongside a strong and expert software and AI team.

Sonio had made exceptional progress for a Series A stage company when the company began conversations with its investors. In fact, the company had already secured the CE mark on some of its products and was actively pursuing FDA approval on several applications as well — some of which have since been achieved.

The combination of these factors not only increased the company’s credibility but also opened the door to an early exit, making Sonio an attractive investment opportunity for firms focused on both impact and financial success.

With its innovative solutions, regulatory excellence, and global ambitions, Sonio continues to break new ground in prenatal healthcare, bringing technology, training, and expertise together in one powerful platform.

As the company continues to grow and innovate under the Samsung umbrella, its impact on maternal-foetal health will only expand, potentially saving countless lives along the way.

Find out more about Sonio at sonio.ai

Image: Sonio

Four considerations for evaluating GenAI for femtech
Women more likely than men to die after heart surgery complications